Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-…

Total and free endotoxin release in time from cultures of Escherichia coli by different
antibiotics was studied in vitro for 4 h in relation to the antibiotic effect on viable counts and …

Objective: To study the patterns of plasma concentrations of endotoxin, tumor necrosis factor-[alpha](TNF),
interleukin-6 (IL-6), plasminogen activator inhibitor-1, C-reactive protein, and …

Background Clinicians need to rapidly and reliably diagnose coronavirus disease 2019 (COVID-19)
for proper risk stratification, isolation strategies, and treatment decisions. Purpose …

Background Direct-acting antivirals effectively treat chronic hepatitis C virus (HCV) infection
but there is a paucity of data on their efficacy for acute HCV, when immediate treatment …

Background: The Netherlands strives for hepatitis C virus (HCV) elimination, in accordance
with the World Health Organization targets. An accurate estimate when HCV elimination will …

Background Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei,
is an opportunistic infection across the tropics. Here, we provide a systematic overview of …

Sepsis or septic shock is frequently associated with activation of the complement system,
coagulation and fibrinolytic changes and the release of several cytokines. In this study we …

Recently, in vitro studies have shown endotoxin release when Gram-negative bacteria are
exposed to antibi-otics. 1-3 Direct evidence that antibiotic therapy can pro-mote endotoxin …